A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-08 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Peripherally selective trans-3,4-dimethyl-4-(3-hydroxylphenyl)piperidine opioid antagonists were developed for the treatment of gastrointestinal motility disorder by Zimmerman and his coworkers. From that, they derived the 4-(3-hydroxyphenyl)-3,4-dimethylpiperidine scaffold with functional groups spanning various sizes, charge, and polarity to reach peripheral opioid receptor antagonism while decreasing CNS drug exposure. The in vitro μ-Ki, in vivo AD50, and ED50 and peripheral index (ratio) was examined for several selective analogs, and from that, they found out that the trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, Alvimopan, gave the best results. The large zwitterionic structure and the high polarity prevents Alvimopan from crossing the blood–brain barrier, potency at binding peripheral MORs is thereby 200 times that of central MORs.
"The Science of Addiction: Genetics and the Brain". learn.genetics.utah.edu. Learn.Genetics – University of Utah. Why do our brains get addicted? – a TEDMED 2014 talk by Nora Volkow, the director of the National Institute on Drug Abuse at NIH. Kyoto Encyclopedia of Genes and Genomes (KEGG) signal transduction pathways: KEGG – human alcohol addiction KEGG – human amphetamine addiction KEGG – human cocaine addiction
=== Insect decline === Both number of insects and number of insect species have declined dramatically and continuously over past decades, causing much concern. Many causes are proposed to contribute to this decline, the most agreed upon are loss of habitat, intensification of farming practices, and insecticide usage. Domestic bees were declining some years ago but population and number of colonies have now risen both in the USA and worldwide. Wild species of bees are still declining.
According to the official website of CBSE, there are 28 government- and private-affiliated schools in various countries outside India. The reason for their establishment is mainly to serve the Indian community abroad, or at least children or relatives of Indian diplomats. In countries where the population of Indian nationals surpasses the country's native population or where they form a substantial share of the population, like Saudi Arabia, the United Arab Emirates, Oman, Qatar, Bahrain, etc., Indian embassies have established CBSE schools and allowed Indians or locals to establish private CBSE schools serving the needs of Indians in those particular countries. But in countries where Indians do not reside, Indian diplomatic missions have established schools, such as those in Russia and Iran, which mainly serve the children of diplomats.
=== Breastfeeding === Progestogen-only contraceptives such as an IUD are not believed to affect milk supply or infant growth. However, a study in the Mirena application for FDA approval found a lower continuation of breastfeeding at 75 days in hormonal IUD users (44%) versus copper IUD users (79%). When using Mirena, about 0.1% of the maternal dose of levonorgestrel can be transferred via milk to the nursed infant. A six-year study of breastfed infants whose mothers used a levonorgestrel-only method of birth control found the infants had increased risk of respiratory infections and eye infections, though a lower risk of neurological conditions, compared to infants whose mothers used a copper IUD. No longer-term studies have been performed to assess the long-term effects on infants of levonorgestrel in breast milk. There are conflicting recommendations about use of Mirena while breastfeeding. The U.S. CDC does not recommend any hormonal method as a first choice of contraceptive for nursing mothers, although progestin-only methods, such as Mirena, may be used with close follow-up or when the benefits outweigh the risks. The World Health Organization recommends against immediate postpartum insertion, citing increased expulsion rates. It also reports concerns about potential effects on the infant's liver and brain development in the first six weeks postpartum. However, it recommends offering Mirena as a contraceptive option beginning at six weeks postpartum even to nursing women.
Sources: en.wikipedia.org
PKU is an autosomal recessive metabolic genetic disorder. As such, two PKU alleles are required for an individual to experience symptoms of the disease. For a child to inherit PKU, both parents must have and pass on the defective gene. If both parents are carriers for PKU, any child they have will have a 25% chance to be born with the disorder, a 50% chance the child will be a carrier, and a 25% chance the child will neither develop nor be a carrier for the disease. PKU is characterized by homozygous or compound heterozygous mutations in the gene for the hepatic enzyme phenylalanine hydroxylase (PAH), rendering it nonfunctional. This enzyme is necessary to metabolize the amino acid phenylalanine (Phe) to the amino acid tyrosine. When PAH activity is reduced, Phe accumulates and is converted into phenylpyruvate (also known as phenylketone), which can be detected in the urine. Carriers of a single PKU allele do not exhibit symptoms of the disease, but appear to be protected to some extent against the fungal toxin ochratoxin A. Louis Woolf suggested that this accounted for the persistence of the allele in certain populations, in that it confers a selective advantage—in other words, being a heterozygote is advantageous. The gene for PAH is located on chromosome 12 in the bands 12q22-q24.2. As of 2000, around 400 disease-causing mutations had been found in the PAH gene. This is an example of allelic genetic heterogeneity.
== Structure == Fibrous bands anchoring the skin to the deep fascia Collagen and elastin fibers attaching it to the dermis Fat is absent from the eyelids, clitoris, penis, much of pinna, and scrotum Blood vessels on route to the dermis Lymphatic vessels on route from the dermis The glandular part of some sweat glands; mammary glands lie entirely within the subcutaneous tissue (which are modified apocrine sweat glands) Cutaneous nerves and free endings Hair follicle roots Ruffini and Pacinian corpuscles Mast cells Bursae, in the space overlying joints in order to facilitate smooth passage of overlying skin Fine, flat sheets of muscle, in certain locations, including the scalp, face, hand, nipple, and scrotum, called the panniculus carnosus The hypodermis forms an important insulating layer and/or food store in some animals, such as whales and hibernating mammals. In some plants, the hypodermis is a layer of cells immediately below the epidermis of leaves. It is often mechanically strengthened, for example, in pine leaves, forming an extra protective layer or a water storage tissue.
=== Europe === As of 2011, the plant was controlled in Denmark, Latvia, Lithuania, Poland, Romania, and Sweden. In Bulgaria and Norway, kratom is a controlled substance. In the Czech Republic, regulated sales of kratom and kratom extracts became legal starting in July 2025. In Finland, scheduled in the "government decree on psychoactive substances banned from the consumer market". In the Republic of Ireland in 2017, kratom was designated a Schedule 1 illegal drug (the highest level), under the names 7-hydroxymitragynine and mitragynine. In the UK, the sale, import, and export of kratom is prohibited under the Psychoactive Substances Act 2016, which broadly bans any substance that "produces a psychoactive effect".
On 3 April 2007, The Boston Globe reported that tainted wheat gluten ended up in factories that produce food for human consumption. Then, on 19 April, federal U.S. officials said that they were investigating reports that Binzhou Futian rice protein had been used in hog feed, but declined to specify where. The California Department of Food and Agriculture placed American Hog Farm in Ceres, California under quarantine, after melamine was found in the urine of the hogs on the farm. According to California state officials, approximately 45 state residents consumed pork from hogs that had been fed melamine-contaminated feed. The FDA subsequently discovered that melamine was present in feed that had been given to hogs in California, New York, North Carolina, South Carolina, Utah, and possibly Ohio. In response, the FDA announced that, in addition to its existing practice of testing of wheat gluten and rice protein products for melamine, it would begin testing imported ingredients and finished products that contain cornmeal, corn gluten, rice bran and soy protein for the presence of melamine or cyanuric acid. The agency also subjected all vegetable proteins imported from China, intended for human or animal consumption, to detention without physical examination, beginning on 27 April. Finally, the FDA investigated domestic food manufacturers to ensure that no contaminated product was being used in foods intended for human use.
Sources: en.wikipedia.org
The unit cell of these phases has double Bi–O planes which are stacked in a way that the Bi atom of one plane sits below the oxygen atom of the next consecutive plane. The Ca atom forms a layer within the interior of the CuO2 layers in both Bi-2212 and Bi-2223; there is no Ca layer in the Bi-2201 phase. The three phases differ with each other in the number of cuprate planes; Bi-2201, Bi-2212 and Bi-2223 phases have one, two and three CuO2 planes, respectively. The c axis lattice constants of these phases increases with the number of cuprate planes (see table below). The coordination of the Cu atom is different in the three phases. The Cu atom forms an octahedral coordination with respect to oxygen atoms in the 2201 phase, whereas in 2212, the Cu atom is surrounded by five oxygen atoms in a pyramidal arrangement. In the 2223 structure, Cu has two coordinations with respect to oxygen: one Cu atom is bonded with four oxygen atoms in square planar configuration and another Cu atom is coordinated with five oxygen atoms in a pyramidal arrangement.
=== Anxiety === Benzoctamine's main clinical use is for the treatment of anxiety, and evidence points to it being as effective as other clinical anxiety drugs, in particular diazepam. In the treatment of symptoms of mild anxiety due to psychoneurosis, a daily dosage of 30 to 80 mg of benzoctamine was shown to be just as effective as 6–20 mg of diazepam. In another study one group of patients were given 10 mg of benzoctamine three times a day, while another group was given 5 mg of diazepam, and the treatments were equivalent. While these studies point to higher doses of benzoctamine being needed to exert the same pharmacological effects, the drug is still popular because of its ability to act as an anxiolytic without producing the common respiratory depression associated with other sedative drugs. Some studies have even shown that it stimulates the respiratory system.
DHX8 has multiple molecular functions like ATP-binding by, selective and non-covalent interactions with the coenzyme and enzyme regulator adenosine 5' triphosphate. Also identical protein binding (creates a similar type of interactions as described above but with other proteins), RNA binding and RNA helicase activity, based on catalysis of the reaction that unwinds an RNA helix: ATP + H2O = ADP + phosphate
=== Scholarly articles === Barron, Lee. "Pulling Down Barriers: Neil Peart, Autobiographical Confession and Negotiated Rock Celebrity", Celebrity Studies, Vol. 7 No. 3, 2016, pp. 323–338. Bowman, Durrell S. "Let Them All Make Their Own Music: Individualism, Rush and the Progressive / Hard Rock Alloy", in Progressive Rock Reconsidered, Kevin Holm-Hudson (ed), Routledge, 2002. Connolly, T. "Mean, Mean Pride: Rush's Critique of American Cool", in T. Connolly and T. Iino (eds), Canadian Music and American Culture. Palgrave MacMillan, 2017. Friedman, Jonathan C. "Performing Grief: The Music of Three Children of Holocaust Survivors: Geddy Lee, Yehuda Poliker, and Mike Brant", Journal of Modern Jewish Studies, Vol. 16 No. 1, 2017, pp. 153–167. Horwitz, Steve. "Rand, Rush, and De-totalizing the Utopianism of Progressive Rock", Journal of Ayn Rand Studies, Vol. 5 No. 1, Fall 2003, pp. 161–172. McDonald, Chris. "Grand Designs: A Musical, Social and Ethnographic Study of Rush", PhD dissertation in ethnomusicology, York University, 2002. McDonald, Chris. "'Making Arrows Out of Pointed Words': Critical Reception, Taste Publics and Rush", Journal of American and Comparative Cultures, Volume 25 No. 3-4, September 2002, pp. 249–259. McDonald, Chris. "'Open Secrets': Individualism and Middle-Class Identity in the songs of Rush", Popular Music and Society Volume 31 No. 3, July 2008, pp. 313–328. Sciabarra, Chris. "Rush, Rand and Rock", Journal of Ayn Rand Studies, Vol. 4 No. 1, Fall 2002, pp. 161–185. Walsh, Brian.
But it did get a little close there for a while. As you may know, there were 61 planes in the air headed toward Haïti at the time they finally agreed. And at one point General Biamby came in and told General Cédras that he had just gotten word on his telephone that the airplanes had taken off from Pope Air Force Base, with soldiers from Fort Bragg, and that both disconcerted them and caused them to be suspicious of the intent of the negotiations, but it also created a situation where immediately after that, the key points they had been refusing to agree to were agreed to, a date certain, other matters that I won't go into in detail here.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.